Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EBT (2016 - 2025)

Historic EBT for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$10.3 million.

  • vTv Therapeutics' EBT fell 7714.04% to -$10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.4 million, marking a year-over-year decrease of 2552.08%. This contributed to the annual value of -$22.6 million for FY2024, which is 1294.38% up from last year.
  • As of Q3 2025, vTv Therapeutics' EBT stood at -$10.3 million, which was down 7714.04% from -$7.4 million recorded in Q2 2025.
  • Over the past 5 years, vTv Therapeutics' EBT peaked at -$841000.0 during Q2 2021, and registered a low of -$10.3 million during Q3 2025.
  • Its 5-year average for EBT is -$6.1 million, with a median of -$5.9 million in 2021.
  • Over the last 5 years, vTv Therapeutics' EBT had its largest YoY gain of 8314.97% in 2021, and its largest YoY loss of 69010.58% in 2021.
  • Quarter analysis of 5 years shows vTv Therapeutics' EBT stood at -$9.5 million in 2021, then skyrocketed by 35.78% to -$6.1 million in 2022, then increased by 27.08% to -$4.4 million in 2023, then increased by 0.09% to -$4.4 million in 2024, then crashed by 133.15% to -$10.3 million in 2025.
  • Its EBT stands at -$10.3 million for Q3 2025, versus -$7.4 million for Q2 2025 and -$6.2 million for Q1 2025.